Researchers gathered real-world data on biologic therapy to determine the feasibility of targeting clinical remission when treating patients with severe asthma.
Early improvement was linked to lower baseline FEV1 and higher eosinophils in severe eosinophilic asthma, while late improvement was linked to high ACT scores.